MKI67P1

Across TCGA pan-cancer cohorts, MKI67P1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated MKI67P1 data layer.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher MKI67P1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MKI67P1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

PRAD, BLCA, and KIRC are the cancer types where MKI67P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.837	0.927	.001	36	view →
BLCA	OS	Median	All	0.573	0.344	.002	31	view →
KIRC	DFS	Quartile	All	0.456	0.687	.006	26	view →
MESO	DFS	Tertile	All	0.247	0.416	.012	18	view →
SKCM	OS	Tertile	III,IV	0.875	0.629	.003	16	view →
THCA	OS	Median	IV	0.566	0.924	.010	14	view →
ESCA	DFS	Quartile	IV	0.095	0.496	.045	12	view →
LUSC	DFS	Tertile	II,III,IV	0.426	0.745	.014	12	view →
HNSC	DFS	Median	All	0.544	0.711	.008	11	view →
READ	DFS	Tertile	IV	0.424	0.820	.007	8	view →
STAD	OS	Tertile	II,III,IV	0.431	0.705	.028	7	view →
UCEC	OS	Tertile	All	0.897	0.939	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

MKI67P1–PRAD (DFS)

Open the PRAD breakdown →